Arvinas, Inc. (ARVN)
Automate Your Wheel Strategy on ARVN
With Tiblio's Option Bot, you can configure your own wheel strategy including ARVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARVN
- Rev/Share 5.8883
- Book/Share 9.1048
- PB 0.7908
- Debt/Equity 0.0159
- CurrentRatio 4.578
- ROIC -0.123
- MktCap 525538080.0
- FreeCF/Share -3.4869
- PFCF -2.0789
- PE -11.2017
- Debt/Assets 0.0105
- DivYield 0
- ROE -0.0774
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ARVN | Truist | Buy | Hold | -- | $11 | May 5, 2025 |
| Downgrade | ARVN | Jefferies | Buy | Hold | -- | $10 | May 2, 2025 |
| Downgrade | ARVN | TD Cowen | Buy | Hold | -- | -- | May 2, 2025 |
| Downgrade | ARVN | Goldman | Buy | Neutral | $70 | $15 | March 13, 2025 |
| Downgrade | ARVN | Wedbush | Outperform | Neutral | $57 | $12 | March 12, 2025 |
| Downgrade | ARVN | Oppenheimer | Outperform | Perform | -- | -- | March 11, 2025 |
| Initiation | ARVN | BTIG Research | -- | Buy | -- | $69 | Dec. 10, 2024 |
News
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m.
Read More
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader.
Read More
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –
Read More
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies
Read More
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers –
Read More
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader – – Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –
Read More
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Published: March 11, 2025 by: Benzinga
Sentiment: Negative
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.
Read More
Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 228.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Arvinas, Inc. (NASDAQ:ARVN ) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Jonathan Miller - Evercore ISI Li Watsek - Cantor Fitzgerald Akash Tewari - Jefferies Group LLC Tazeen Ahmad - Bank of America Srikripa Devarakonda - Truist Securities Jeet Mukherjee - BTIG, LLC Bradley Canino - Stifel Financial Corp. Sudan …
Read More
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – – Initiated a Phase 1 …
Read More
About Arvinas, Inc. (ARVN)
- IPO Date 2018-09-27
- Website https://www.arvinas.com
- Industry Biotechnology
- CEO Dr. John G. Houston Ph.D.
- Employees 430